4.5 Article

Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia

Journal

Publisher

SPRINGER
DOI: 10.1007/s10096-010-0993-0

Keywords

-

Funding

  1. Fundacion Pi I Sunyer
  2. FUCAP (Fundacio Catalana de Pneumologia)
  3. Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spanish Network for the Research in Infectious Diseases [REIPI RD06/0008]
  4. FIS [070864]
  5. Institut d'Investigacio Biomedica de Bellvitge

Ask authors/readers for more resources

The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with beta-lactam monotherapy or with combination therapy (beta-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-alpha were determined on days 0, 1, 2, 3, 5, and 7. Patients on beta-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with beta-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p = 0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Public, Environmental & Occupational Health

Impact of the coronavirus disease 2019 (COVID-19) pandemic on infection control practices in a university hospital

Gabriela Abelenda-Alonso, Mireia Puig-Asensio, Emilio Jimenez-Martinez, Esther Garcia-Lerma, Ana Hornero, Carmen Gutierrez, Miriam Torrecillas, Cristian Tebe, Miquel Pujol, Jordi Carratala

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Article Infectious Diseases

Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)

Francisco Lopez-Medrano, Santiago Alfayate, Jordi Carratala, Judith Chamorro-Camazon, Elisa Cordero, Marta Cruz-Canete, Maria Fernandez-Prada, Manuel Garcia-Cenoz, Maria Angeles Marcos, Santiago Melon, Nemesio Moreno-Millan, Maria Angeles Onieva-Garcia, Raul Ortiz de Lejarazu, Jaime Jesus Perez-Martin, Juan Rodriguez-Garcia, German Schwarz-Chavarri, Alfredo Tagarro-Garcia, Diego van Esso-Arbolave, Diego Viasus, Tomas Pumarola

Summary: "The influenza virus has significant impacts on individuals and society, putting a burden on the health system. This Consensus Document aims to simplify the approach to influenza virus infection and reduce its consequences on population health." (Source: Published by Elsevier Espana, S.L.U. on behalf of the Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica)

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2023)

Letter Infectious Diseases

Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

Alexander Rombauts, Carmen Infante, Mikel del Alamo Martinez de Lagos, Jorge Alba, Adoracion Valiente, Carla Donado-Mazarron, Marta Carretero-Ledesma, Regino Rodriguez-Alvarez, Sonia Omatos, Zaira R. Palacios-Baena, Gabriela Abelenda-Alonso, Maria del Mar Silva-Sanchez, Ane Josune Goikoetxea-Agirre, Jose A. Oteo, Jesus Rodriguez-Bano, Elisa Cordero, Carlota Gudiol, Javier Sanchez-Cespedes, Jordi Carratala

JOURNAL OF INFECTION (2023)

Article Immunology

Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice

Mario Fernandez-Ruiz, Marta Bodro, Isabel Gutierrez Martin, Regino Rodriguez-Alvarez, Maria Ruiz-Ruigomez, Nuria Sabe, Teresa Lopez-Vinau, Maricela Valerio, Aitziber Illaro, Jesus Fortun, Sonsoles Salto-Alejandre, Elisa Cordero, Maria del Carmen Farinas, Patricia Munoz, Elisa Vidal, Jordi Carratala, Josune Goikoetxea, Antonio Ramos-Martinez, Asuncion Moreno, Jose Maria Aguado

Summary: Retrospective study shows that isavuconazole is a safe and effective treatment option for invasive mold disease in solid organ transplantation recipients. Clinical response was achieved in over 50% of patients by weeks 6 and 12, and adverse events were relatively low.

TRANSPLANTATION (2023)

Article Surgery

Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

Elena Perez-Nadales, Mario Fernandez-Ruiz, Alejandra M. Natera, Belen Gutierrez-Gutierrez, Alessandra Mularoni, Giovanna Russelli, Ligia Camera Pierrotti, Maristela Pinheiro Freire, Marco Falcone, Giusy Tiseo, Mario Tumbarello, Francesca Raffaelli, Edson Abdala, Marta Bodro, Elena Gervasi, Maria Carmen Farinas, Elena M. Seminari, Juan Jose Caston, Juan Antonio Marin-Sanz, Victor Galvez-Soto, Meenakshi M. Rana, Belen Loeches, Pilar Martin-Davila, Alvaro Pascual, Jesus Rodriguez-Bano, Jose Maria Aguado, Luis Martinez-Martinez, Julian Torre-Cisneros, REIPI INCREMENT-SOT Study Grp

Summary: This study compared the efficacy of ceftazidime-avibactam (CAZ-AVI) and the best available therapy (BAT) in treating solid organ transplant recipients with bloodstream infection caused by carbapenemase-producing Klebsiella pneumoniae. The results showed that patients treated with CAZ-AVI had higher clinical success rates at 14-day and 30-day and lower 30-day mortality compared to those receiving BAT.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Immunology

Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study

Alexander Rombauts, Marta Bodro, Victor Daniel Gumucio, Irene Carbonell, Alex Fava, Laura Llado, Jose Gonzalez-Costello, Federico Oppenheimer, Maria Angeles Castel-Lavilla, Oscar Len, Ester Marquez-Algaba, Xavier Nuvials-Casals, Daniel Martinez Gonzalez, Judith Sacanell Lacasa, Jordi Carratala, Nuria Sabe

Summary: COVID-19-associated pulmonary aspergillosis (CAPA) is common in the ICU, but little is known about its occurrence in solid organ transplant recipients (SOTRs) and the efficacy of antifungal prophylaxis. A retrospective study compared SOTRs with and without nebulized amphotericin-B prophylaxis, showing a lower incidence of pulmonary mold infections in the prophylaxis group. Nebulized amphotericin-B was found to be safe and potentially effective in reducing the risk of CAPA in SOTRs with COVID-19. Further randomized clinical trials are needed to confirm these findings.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Article Infectious Diseases

Changing Trends in the Global Consumption of Treatments Used in Hospitalized Patients for COVID-19: A Time Series Multicentre Study

Judit Aranda, Jose Loureiro-Amigo, Anna Murgadella, Nuria Vazquez, Lucia Feria, Miriam Munoz, Ariadna Padulles, Gabriela Abelenda, Carol Garcia-Vidal, Montse Tuset, Marta Albanell, Lucia Boix-Palop, Nuria Sanmarti-Martinez, Silvia Gomez-Zorrilla, Daniel Echeverria-Esnal, Alicia Rodriguez-Alarcon, Beatriz Borjabad, Ana Coloma, Jordi Carratala, Isabel Oriol

Summary: This study analyzed the prescription trends of COVID-19 treatments for hospitalized patients in Barcelona. The use of lopinavir/ritonavir and hydroxychloroquine declined over time and was replaced by remdesivir. Tocilizumab use showed a varying trend, while dexamethasone use increased. Antibiotic use, particularly azithromycin, decreased after the initial months of the pandemic. The findings highlight the importance of adapting treatment strategies based on evolving scientific evidence.

ANTIBIOTICS-BASEL (2023)

Article Infectious Diseases

Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients

Javier Martinez-Casanova, Erika Esteve-Pitarch, Helena Colom-Codina, Victor Daniel Gumucio-Sanguino, Sara Cobo-Sacristan, Evelyn Shaw, Kristel Maisterra-Santos, Joan Sabater-Riera, Xose L. Perez-Fernandez, Raul Rigo-Bonnin, Fe Tubau-Quintano, Jordi Carratala, Ariadna Padulles-Zamora

Summary: This study aimed to characterize the pharmacokinetics of piperacillin after continuous infusion administration in critically ill adult patients and determine the optimal dosing regimen. The population pharmacokinetic approach was used to analyze piperacillin concentrations from 106 patients. Creatinine clearance was found to be the most predictive factor of piperacillin clearance. The model developed can be used for initial dose guidance and therapeutic drug monitoring.

ANTIBIOTICS-BASEL (2023)

Article Biochemistry & Molecular Biology

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19

Alexander Rombauts, Marta Bodalo Torruella, Gabriela Abelenda-Alonso, Julia Perera-Bel, Anna Ferrer-Salvador, Ariadna Acedo-Terrades, Maria Gabarros-Subira, Isabel Oriol, Carlota Gudiol, Lara Nonell, Jordi Carratala

Summary: The clinical manifestations of SARS-CoV-2 infection vary widely, from asymptomatic infection to severe respiratory complications. The host response to the virus plays a crucial role in determining the outcomes. This study aimed to understand the differences in gene expression and immune response in COVID-19 patients with and without acute respiratory distress syndrome (ARDS). Blood samples were collected from 60 hospitalized patients with confirmed SARS-CoV-2 infection, and significant differences in gene expression were found between the ARDS and non-ARDS groups, including dysregulated inflammatory response and altered immune regulation.

BIOMEDICINES (2023)

Article Biochemistry & Molecular Biology

Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

Sara Grillo, Miquel Pujol, Josep M. Miro, Joaquin Lopez-Contreras, Gorane Euba, Oriol Gasch, Lucia Boix-Palop, Maria Jose Garcia-Pais, Maria Teresa Perez-Rodriguez, Silvia Gomez-Zorrilla, Isabel Oriol, Luis Eduardo Lopez-Cortes, Maria Luisa Pedro-Botet, Rafael San-Juan, Jose Maria Aguado, Francesca Gioia, Simona Iftimie, Laura Morata, Alfredo Jover-Saenz, Graciano Garcia-Pardo, Belen Loeches, Alvaro Izquierdo-Cardenas, Ane Josune Goikoetxea, Aina Gomila-Grange, Beatriz Dietl, Damaris Berbel, Sebastian Videla, Pilar Hereu, Ariadna Padulles, Natalia Pallares, Cristian Tebe, Guillermo Cuervo, Jordi Carratala, SAFO Study Grp

Summary: In hospitalized adults with MSSA bacteremia, combining cloxacillin with fosfomycin did not achieve better treatment success at day 7 compared to using cloxacillin alone. Further trials should consider the heterogeneity of the infection and use a personalized approach.

NATURE MEDICINE (2023)

Article Virology

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Jose Luis Pinana, Inmaculada Heras, Tommaso Francesco Aiello, Irene Garcia-Cadenas, Lourdes Vazquez, Javier Lopez-Jimenez, Pedro Chorao, Cristina Aroca, Carolina Garcia-Vidal, Ignacio Arroyo, Eva Soler-Espejo, Lucia Lopez-Corral, Alejandro Avendano-Pita, Anna Arrufat, Valentin Garcia-Gutierrez, Elena Arellano, Lorena Hernandez-Medina, Clara Gonzalez-Santillana, Julia Morell, Jose angel Hernandez-Rivas, Paula Rodriguez-Galvez, Mireia Mico-Cerda, Manuel Guerreiro, Diana Campos, David Navarro, Angel Cedillo, Rodrigo Martino, Carlos Solano

Summary: This study analyzed the outcomes of hematological patients with SARS-CoV-2 infection who received treatment with remdesivir or nirmatrelvir/ritonavir. The results showed that nirmatrelvir/ritonavir was safe and effective for treating mild cases, while remdesivir was preferred for moderate to severe cases with a higher mortality rate. Factors such as male gender, corticosteroid use, and co-infection were associated with worse outcomes in patients treated with remdesivir.

VIRUSES-BASEL (2023)

Review Medicine, General & Internal

Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review

Francisco Javier Candel, Miguel Salavert, Angel Estella, Miquel Ferrer, Ricard Ferrer, Julio Javier Gamazo, Carolina Garcia-Vidal, Juan Gonzalez del Castillo, Victor Jose Gonzalez-Ramallo, Federico Gordo, Manuel Miron-Rubio, Javier Perez-Pallares, Cristina Pitart, Jose Luis del Pozo, Paula Ramirez, Pedro Rascado, Soledad Reyes, Patricia Ruiz-Garbajosa, Borja Suberviola, Pablo Vidal, Rafael Zaragoza

Summary: Nosocomial pneumonia and ventilator-associated pneumonia are significant global health problems, causing high morbidity and mortality rates. This scientific manuscript reviews important aspects of the management of these infectious respiratory syndromes, providing updates on etiological perspectives, diagnostic techniques, treatment options, and preventive strategies.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Infectious Diseases

Voriconazole Pharmacokinetics in Critically Ill Patients and Extracorporeal Membrane Oxygenation Support: A Retrospective Comparative Case-Control Study

Mar Ronda, Josep Manuel Llop-Talaveron, MariPaz Fuset, Elisabet Leiva, Evelyn Shaw, Victor Daniel Gumucio-Sanguino, Yolanda Diez, Helena Colom, Raul Rigo-Bonnin, Mireia Puig-Asensio, Jordi Carratala, Ariadna Padulles

Summary: This study compared the pharmacokinetics of voriconazole in critically ill patients with and without extracorporeal membrane oxygenation (ECMO) support. The results showed that the ECMO group had lower minimum plasma concentration (C-min) and a higher prevalence of subtherapeutic C-min values. ECMO support and plasma albumin levels were identified as risk factors for low C-min values. Drug optimization is crucial for achieving therapeutic C-min levels in the ECMO group.

ANTIBIOTICS-BASEL (2023)

Review Biochemistry & Molecular Biology

A Systematic Review of Gene Expression Studies in Critically Ill Patients with Sepsis and Community-Acquired Pneumonia

Diego Viasus, Lara Nonell, Carlos Restrepo, Fabian Figueroa, Carla Donado-Mazarron, Jordi Carratala

Summary: This study summarizes the reported differentially expressed genes (DEGs) in critically ill septic patients with community-acquired pneumonia (CAP) and investigates their functional implications. The results highlight the complexity of immune responses during CAP.

BIOMEDICINES (2023)

Article Immunology

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

Tomas O. Jensen, Greg A. Grandits, Mamta K. Jain, Thomas A. Murray, Birgit Grund, Kathryn Shaw-Saliba, Michael A. Matthay, Mahsa Abassi, Magdalena Ardelt, Jason V. Baker, Peter Chen, Robin L. Dewar, Anna L. Goodman, Timothy J. Hatlen, Helene C. Highbarger, Mark Holodniy, Perrine Lallemand, Sylvain Laverdure, Bradley G. Leshnower, David Looney, Charalampos D. Moschopoulos, Henry Mugerwa, Daniel D. Murray, Eleftherios Mylonakis, Stephanie Nagy-Agren, M. Tauseef Rehman, Adam Rupert, Randy A. Stevens, Stuart Turville, Amy Weintrob, Katherine Wick, Jens Lundgren, Emily R. Ko

Summary: This study suggests that neutralizing monoclonal antibodies have an antiviral effect among hospitalized patients with COVID-19, without affecting the endogenous anti-nucleocapsid antibody response, systemic inflammation, or clinical status on day 5.

JOURNAL OF INFECTIOUS DISEASES (2023)

No Data Available